Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-Label, Multicenter, Single-Arm, Interventional Study to Evaluate the Efficacy and Tolerability of Once-Daily Oros Hydromorphone for Cancer Pain Treatment in Korean Cancer Patients.

NCT01621100 is registered in ClinicalTrials.gov with Janssen Korea, Ltd., Korea as lead sponsor.

NCT NCT01621100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01621100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-Label, Multicenter, Single-Arm, Interventional Study to Evaluate the Efficacy and Tolerability of Once-Daily Oros Hydromorphone for Cancer Pain Treatment in Korean Cancer Patients.
Lead sponsor
Janssen Korea, Ltd., Korea
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2011
Completion date
September 30, 2012
Enrollment
106 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cancer pain